The submission also appears to be the first worldwide for a once-weekly DPP-4 inhibitor, a class now administered once a day, and assuming normal regulatory review times in Japan may result in an approval there in around a year's time.
written on 10.03.2014
First filing for Takeda's once-weekly DPP-4 inhibitor but prospects limited?
